Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib

rgeted treatment for advanced soft tissue sarcoma: profile of pazopanib Review (264) Total Article Views Authors: Rajendra R, Jones RL, Pollack SM Published Date March 2013 Volume 2013:6 Pages 217 - 222 DOI: http://dx.doi.org/10.2147/OTT.S32200 Received: 11 December 2012 Accepted: 04 February 2013 Published: 18 March 2013 Rajeev Rajendra, Robin L Jones, Seth M Pollack University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA Abstract: Soft tissue sarcomas comprise approximately 1% of all adult solid malignancies. While chemotherapy is the mainstay of treatment for patients with metastatic or inoperable disease, overall survival for these patients is approximately 12 months, highlighting the need for novel agents. Both laboratory and clinical data have suggested that antiangiogenic agents may have a role in the treatment of soft tissue sarcomas. Pazopanib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic activity. The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. In this review, we discuss the rationale and clinical evidence for the use of pazopanib in the treatment of metastatic and inoperable soft tissue sarcomas.